Operative terms here are: an appropriate hydrogen distribution network in place and Lotus Engineering
A series hybrid configuration using the hydrogen powered fuel cell developed by Intelligent Energy acting as the range extender is the solution in this collaboration. The hydrogen powered fuel cell acts as the range extender to electric drive with a smaller battery pack and creates a total powertrain with zero tailpipe emissions. With an appropriate hydrogen distribution network in place, the fuel cell could be replenished quickly in service, unlike charging the battery of a pure electric vehicle.
With LTi as the vehicle manufacturer and TRW Contekt conducting the safety analysis and supplying some of the systems,, Lotus Engineering's role is in this project is as the technology and vehicle integrator. It encompasses a variety of activities to ensure all the systems in the new propulsion system are robustly installed in the vehicle and that the systems work seamlessly together operate the vehicle efficiently and reliably.To achieve acceptance and be able to operate in London the vehicle must have comparable performance with the standard vehicle, but also be able to meet all the requirements of the Public Carriage Office: turning circle, passenger access, carrying capabilities etc. Also it was a requirement that the external appearance of the instantly recognised London Taxi must not be altered.
The fuel cell system is a development of two Intelligent Energy single stack evaporatively cooled modules which together provide an output of 30 kW. A single air delivery subsystem reduces system losses and is mounted remotely from the main fuel cell power module to aid packaging. A bespoke liquid/liquid plate heat exchanger enables the heat generated to be used in conjunction with waste heat from other electrical components to heat the vehicle cabin. This is then coupled to a conventional radiator located at the front of the vehicle to remove excess heat. The stacks are
To be clear, the diseases we treat are some of the most complex life-threatening conditions in medicine for which no effective therapies exist, and where the risk of death is still one in every three patients despite the best medical treatment. We have no expectation that CytoSorbÂ® will work every time. But with the collaboration and experience of a growing number of physicians who have collectively performed more than 5,500 human treatments to date, we have made significant progress toward identifying which diseases and patients best respond to CytoSorbÂ® therapy. Centralized data from our recently launched International CytoSorbÂ® Registry and from the more than 50 planned investigator-initiated and company-sponsored studies (a dozen of which are already enrolling patients), will also be invaluable to understanding the full potential of CytoSorbÂ®. We now have the funding and clinical development team to advance our trial agenda more aggressively, particularly in the areas of sepsis and cardiac surgery - our two largest markets.
Before I conclude, I should comment on the potential use of CytoSorbÂ® as a rescue therapy for "cytokine release syndrome", or CRS, that can lead to cytokine storm in activated T-cell immunotherapy cancer treatments. This is one of the most promising and exciting areas of cancer research where a patient's own white blood cells (T-cells) are engineered to recognize and kill cancer cells. This is a strategy being pursued by major corporate and university alliances such as Novartis/University of Pennsylvania, Juno Therapeutics/Memorial Sloan Kettering/Fred Hutchinson Cancer Center/Seattle Children's Research Institute, Celgene/Bluebird Bio, Kite Pharma/National Cancer Institute, GlaxoSmithKline/Adaptimmune, Merck KGaA/Intrexon/MD Anderson, and Pfizer/Cellectis. In a number of studies, the use of activated T-cells has led to the "cure" or remission of many refractory leukemias and other cancers. Common to all of these activated T-cell therapies is the potent stimulation of the inflammatory response, leading to an expected extended "flu-like" syndrome in patients, characterized by high levels of cytokines. However, CRS can spiral out of control, despite the use of tocilizumab and other prophylactic measures, leading rapidly to multiple organ failure and often death. CRS is exactly what CytoSorbÂ®was designed to control and we believe that CytoSorbÂ® represents a potentially unique rescue therapy to treat immune overstimulation in T-cell immunotherapy. While we are still in the beginning phases of exploring this new opportunity, CytoSorbents already has several initiatives underway.
Japanese firm to launch a transportable power generator that doesn’t produce carbon dioxide !
plans to roll out a transportable hydrogen power generator later this year that doesn’t produce carbon dioxide in the process, thereby getting around the main drawback tarnishing hydrogen’s reputation for clean energy.
The company hopes to market its power generating system by the end of September in what represents its first step toward developing technologies for mass producing hydrogen using renewable energy.
Hydrogen is seen as an energy of the future because it doesn’t emit CO2 when it is used in fuel cells. But most hydrogen commercially used across the world is produced from fossil fuels, such as coal and natural gas, that produce CO2 in the process.
Amid growing concerns about global warming, Japanese companies such as Chiyoda Corp. and Kawasaki Heavy Industries Ltd. are competing to develop CO2-free hydrogen technology that is not too costly.
Toshiba’s system, called H2One, consists of a 30-kilowatt solar panel, a hydrogen producing unit, hydrogen storage tank, fuel cell, battery and water storage tank, all installed in a shipping container-sized unit for easy transportation. The generator can supply electricity and hot water for about 300 people for about a week, said Hiroyuki Ota, senior manager of Toshiba’s New Energy Solution Project.
Mr. Ota declined to give a specific price for the unit, but said it would be priced at “about two-thirds of a lithium-ion battery system with the same capability.”
Toshiba aims to sell 50 units by the end of March 2016, and has already received several orders, he told reporters at a news conference about the system.
The Japanese government and domestic companies are accelerating their efforts to advance hydrogen technology in readiness for the 2020 Tokyo Olympic Games, which is seen as a major promotional opportunity. To that end the Ministry of Economy, Trade and Industry devised a hydrogen and fuel cell strategy road map last year.
he therapy called MultiStem, which was company's only product to reach human trials, failed a mid-stage trial that tested it as a treatment for ischemic strokes, which account for approximately 87% of all stroke cases.
The study tested the safety and efficacy of the treatment when given between 24 and 48 hours after an ischemic stroke. The data showed that MultiStem was not better than a placebo when given after 36 hours, but it also demonstrated that the therapy had better efficacy when given before 36 hours.
"Unfortunately, we just didn't have the window right for this study," Athersys COO William Lehmann told Reuters. "We believe investors should see this as a sign that MultiStem works."
The stock's free fall on Friday eliminated more than 40% of the company's market value.
Southern California Gas Co. has started two pilot projects that will test the feasibility of using solar energy produced when power demand is low to split hydrogen from water and store the gas in pipelines.
The projects, backed by U.S. government funding, will either ship the hydrogen for use as an automotive fuel or combine it with carbon dioxide to form methane that can be used to generate electricity when demand is stronger.
The company is pitching the technology, already used in Germany with wind energy, as an alternative to battery storage. Renewable fuels must make up a third of California’s power supply by 2020, according to state law.
“I think everyone knows that in meeting that requirement you will need a lot of storage,” Jeffrey Reed, director of business strategy and advanced technology for the utility, a unit of San Diego-based Sempra Energy, said in an April 9 phone interview. “We need resources to match the time of production with the time of use.”
The cost of storing power converted to gas is less than 35 cents per kilowatt-hour, according to analysis by Southern California Gas.
Once put onto the pipeline network system, wholesale power prices and the price of gasoline at the pump will determine how those gases are used, said Patrick Lee, senior vice president of customer service, innovation and business strategy for the utility in Los Angeles.
“It’s really a flexible fuel that depends on the market economics,” said Lee. “It’s especially suitable for long-term storage.” Germany is already using the process with surplus wind produced overnight, he said.
As part of the projects, the National Renewable Energy Laboratory in Golden, Colorado, will produce the hydrogen and combine it with carbon dioxide, a greenhouse gas linked to global warming, to make methane with a negative carbon footprint, Reed said. The National Fuel Cell Research Center at University of California, Irvine, will test the hydrogen for vehicle use and
Look below for: antimicrobial resistance (AMR)
"Next year, 2016 promises to be a hugely historic moment for the world and China when China becomes the chair of the G20 in January. This is a chance for China to show that it is both capable and eager to take more global responsibility, consistent with its economic might. China should seek to lead the G20 by placing policies on the agenda that it would not face opposition from the rest of the world. In this regard, I am pursuing dialogue with friends and acquaintances in policy circles to suggest that China should place the topic of antimicrobial resistance (AMR) front and centre of that agenda. I am currently leading a Review for the UK Prime Minister to find a solution to this massive, global and shared problem and am eager for this challenge to be elevated to becoming a G20 issue. we are all heading to an environment where we are going to be resistant to antibiotics which will endanger the health of society around the world as we know desire including in hospital treatments as well as for common modern procedures.In a paper, my Review team published in December 2015, we showed that if not solved by 2050, there could be at least 10 million people dying a year, more than one million of which would be in China. We simultaneously showed that there could be a loss of an accumulated $100 trillion of global GDP, and that China and other leading emerging powers would be the most negatively affected. I cannot think of a more fitting development than for China to lead the world through its first G20 hosting and help us all avoid this unnecessary outcome".
Researchers have discovered a way to stimulate muscle regrowth in the heart of a mouse, opening up prospects of new treatments for the 55,000 Australians who experience a heart attack each year.
The animal study found it was possible to regenerate muscle cell numbers in the heart by up to 45%, by ‘turbo-charging’ a hormone that helped coordinate cell growth.
According to study lead author, UNSW Associate Professor Richard Harvey, based at the Victor Chang Cardiac Research Institute, this is an important step toward repairing a broken heart.
“Unlike blood, hair or skin cells, which can renew themselves throughout life, cell division in the heart virtually comes to a standstill shortly after birth, which means the heart can’t fully regenerate if it is damaged later in life,” Professor Harvey said.
“Previous studies have demonstrated that it is possible to coax heart muscle cells to proliferate again, but only at very trivial levels.
“What the research team has been able to do is boost heart muscle cell numbers by as much as 45% after a heart attack.”
The scientists focused on a signalling system in the heart driven by a hormone called ‘neuregulin’.
By switching the neuregulin pathway to ‘turbo charge’, the researchers found that heart muscle cells continued to divide in a spectacular way in both the adolescent and adult periods. Stimulating the neuregulin pathway during a heart attack led to replacement of lost muscle.
“This big achievement will focus the attention of the field on heart muscle cell replacement as a therapeutic option for ischemic heart disease,” Professor Harvey said.
“The dream is that one day we will be able to regenerate damaged heart tissue, much like a salamander can regrow a new limb if it is bitten off by a predator. Just imagine if the heart could learn to regrow and heal itself. That would be the ultimate prize.”
The research, conducted at the Weizmann Institute of Science
On April 1, 2015, Aethlon Medical, Inc. ("we") filed a Certificate of Change with the Secretary of State of the State of Nevada for the purpose of effecting a 1-for-50 reverse stock split of both our authorized and our issued and outstanding common stock. Accordingly, both the issued and outstanding and authorized common stock will be changed in ratio. On April 7, 2015, we filed a further Certificate of Correction with the Secretary of State of the State of Nevada to provide that the reverse stock split will become effective under Nevada law on April 10, 2015. On the effective date, our total authorized shares of common stock will be reduced from 500,000,000 shares to 10,000,000 shares, and each 50 shares of our issued and outstanding common stock held by our stockholders will be combined into one share of our common stock. We will not issue any fractional shares as a result of the reverse stock split. If the reverse stock split would result in the issuance of a fractional share to any stockholder, we will issue one whole share to such stockholder in lieu of the fractional share. The reverse stock split was approved by our Board of Directors. Pursuant to Nevada law, the approval of the stockholders is not required to effect this reverse stock split. Following the effectiveness of the reverse stock split, stockholders who have existing stock certificates will receive written instructions by mail from our transfer agent to exchange their shares of common stock. Stockholders who hold their shares in brokerage accounts or "street name" are not required to take any action to effect the exchange of their shares of common stock.
We have submitted our initial listing application with the Nasdaq Stock Market to have our common stock approved for listing on the Nasdaq Capital Market. Our Board of Directors approved the reverse stock split in part to support the Nasdaq Capital Market listing application. At present, we do not meet all of the initial listing requirements of
Atrial natriuretic peptide (ANP) and brain (B-type) natriuretic peptide (BNP) are circulating hormones of cardiac origin that play an important role in the regulation of intravascular blood volume and vascular tone. The plasma concentrations of ANP and BNP are elevated in heart failure, and they are considered to compensate for heart failure because of their diuretic, natriuretic, and vasodilating actions and inhibitory effects on renin and aldosterone secretion. Evidence is also accumulating from recent work that ANP and BNP exert their cardioprotective functions not only as circulating hormones but also as local autocrine and/or paracrine factors. In studies using cultured neonatal myocytes and fibroblasts, exogenous administration of both ANP and ANP antagonists demonstrated that ANP has antihypertrophic and antifibrotic functions. Corroborating these in vitro results, mice lacking natriuretic receptor-A (NPR-A), the receptor for ANP and BNP, develop cardiac hypertrophy and fibrosis independent of their blood pressure. Recent studies also suggest that the intracardiac natriuretic peptides/cGMP system plays a counter-regulatory role against the intracardiac renin–angiotensin–aldosterone system and TGF-beta mediated pathway. In a clinical setting, human recombinant ANP and BNP may be used for a therapy of heart failure; however, further evaluation is required in the future.
Indiana health officials expect an HIV outbreak that has infected 81 people to grow by dozens more cases, spread with dirty needles by pain-pill addicts who have turned to injecting the drugs.
Unlike with heroin, recreational painkiller users who crush and inject the pills use a wider needle, which makes HIV transmission more likely, said Indiana State Health Commissioner Jerome Adams. So far, most of the people in the Scott County outbreak have tested positive after abusing oxymorphone, a drug that Endo International Plc sells as Opana and is also available as a generic. The area usually sees about five new HIV cases a year.
Scrappy Bay Area clinical stage cancer therapy company Aduro Biotech is celebrating Monday, after announcing drug behemoth Novartis AG (NVS) will pay $200 million upfront to gain a 2.7 percent equity stake in Aduro for $25 million, the companies said. Under the terms of the deal, Novartis will also pour in another $25 million investment, with Aduro eligible for an extra $500 million in milestone payments.
Novartis made the deal primarily to gain access to Aduro’s promising STING (Stimulator of Interferon Genes) receptor technology. The deal will now give it the rights to the worldwide research, development and commercialization of novel immuno-oncology products derived from Aduro’s cyclic dinucleotide (CDN) approach to target STING.
Here we go again.
The Obama administration released a plan Friday to halt the spread of antibiotic-resistant bacteria in the wake of a deadly outbreak at a Los Angeles hospital in February.
The plan seeks to reduce the rates of “superbug” infections in the next five years by pushing doctors and farmers to limit over prescription of antibiotics, according to a White House fact sheet. The federal government will invest in new antibiotic research and require hospitals to increase infection controls.
3/27/2015 8:00:19 AM
Thank you for the extra insight. Plant source ? The name used by AEMD's lectin (or other) comes up as a white flower, another ?
... on Sept. 27, 1999. Young’s head was slammed to the ground. One of the great quarterbacks of his era never played football again.
Young’s concussion — not his first — ended his career at age 37, while he was still at the top of his game. He officially retired from the 49ers at the end of that season. In a conversation about Chris Borland’s surprise retirement from football at age 24, Young said his own health is good but he is tortured by what he sees happening to many of the men he played with and against.
“It’s awful. It’s scary,” Young said. “My generation, people who played with me, they’re suffering from football.”
Young, like others, notes that the decision is different today than it was for players in his era.
The brain disease chronic traumatic encephalopathy “has changed the nature of the risk,” Young said. “This generation is growing up with knowledge that we didn’t have. There will be a wide variety of decisions made and this — retiring early — is one of them.
“And as someone who played in the previous generation, I appreciate it.”
HiTrap Con A 4B
HiTrap Con A 4B is a ready-to-use column prepacked with Con A Sepharose 4B, a medium for convenient separation and purification of glycoproteins, polysaccharides, and glycolipids.
Con A Sepharose is concanavalin A coupled to Sepharose 4B.
HiTrap Con A 4B columns can be operated with a syringe, a peristaltic pump, or a liquid chromatography system such as ÄKTA design.
Concanavalin A (Con A) is a tetrameric metalloprotein isolated from Canavalia ensiformis (jack bean). Con A binds molecules containing α-D-mannopyranosyl, α-D-glucopyranosyl, and sterically related residues. The binding sugar requires the presence of C-3, C-4 and C-5 hydroxyl groups for reaction with Con A. Con A coupled to Sepharose is routinely used for separation and purification of glycoproteins, polysaccharides, and glycolipids.
We offer Sepharose-based affinity chromatography media with immobilized lectin for purification of glycoproteins. Con A Sepharose 4B with concanavalin A (Con A) ligands is useful for isolating mannose and glucose-containing glycoproteins. Lentil Lectin Sepharose 4B also purifies glycoproteins, including detergent-solubilized membrane glycoproteins and viral glycoproteins.
Lectins are proteins that interact specifically and reversibly with certain sugar residues. Their specificity enables binding to polysaccharides and glycoproteins and agglutination of erythrocytes and tumor cells. The interaction between a lectin and a specific sugar residue is analogous to binding between an antibody and an antigen. To select an appropriate lectin-based chromatography media for your purification, it may be necessary to screen different media (resins). Substances bound to the immobilized lectin may be dissociated using a competitive binding substance or an ionic strength gradient.
Immobilized lectins are invaluable tools for isolating and separating glycoproteins, glycolipids, polysaccharides, subcellular particles and cells, and for purifying detergent-solubilized cell membrane components. They also are useful for assessing changes in levels or composition of surface glycoproteins during cell development and in malignant or virally transformed variants.
Often last season, 49ers rookie linebacker Chris Borland was described as an “exceptional” player, one who was making a tremendous impact despite his limited athletic abilities.
Now we’re finding out just how exceptional Borland is.
With his surprise announcement Monday that, at age 24, he was retiring immediately from the NFL because of concerns about the “long-term effects of repetitive head trauma,” Borland set off a national discussion about the dangers of football and the future of the league.
Is Borland just an isolated case? Or is he the canary in the coal mine? An early indicator that growing worries over the long-term health of players are here to stay?
“I definitely think this is something we’re going to see more of in the future,” said former 49er Gary Plummer. “Knowledge is power.”
That’s something that Plummer says he didn’t have in his 12-year NFL career, preceded by a college career at Cal and three years in the USFL. Plummer, who, like Borland, played inside linebacker, is 55 and was diagnosed with early onset dementia in November.
“I had a headache for 11 straight years,” Plummer said.
Borland has more opportunity to gain knowledge than his NFL predecessors, entering the league at a time when health concerns make regular headlines. He read the book “League of Denial” by former Chronicle reporter Mark Fainaru-Wada and his brother Steve Fainaru. The brothers broke the Borland retirement story on ESPN’s “Outside the Lines” on Monday.
Borand did research into the cases of players like Dave Duerson and Ray Easterling, who were diagnosed with chronic traumatic encephalopathy (CTE) after they committed suicide. Borland was said to be especially impacted by the story of Pittsburgh Hall of Fame center Mike Webster, who also committed suicide and, like Borland, played college ball at Wisconsin.
Borland’s father, Jeff, said that from the beginning of his son’s NFL career, he was thinking about playing only one season.
Though Borland isn’t suffering from any concussion-related symptoms, he said he did suffer what he believed was a concussion last summer in training camp, which was sobering. He wondered, “Is this how I’m going to spend my adult life, banging my head?”
Well, yes, if he had continued to play linebacker.
“Your helmet is a weapon, and it always has been,” Plummer said. “It’s a physical mismatch between linebacker and offensive lineman, and it requires helmet to helmet contact. Your helmet is leverage.”
Players at other positions may be able to do a better job at avoiding contact. At linebacker, it’s virtually impossible.
Yet Plummer was in such denial about the trauma to his head that he believed players who retired because of injury were weak. Since he hadn’t been knocked out cold, he didn’t think he’d ever had a concussion. In the mid-1990s, at a panel on concussions organized by agent Leigh Steinberg (a scene described in “League of Denial”), Plummer stood up and yelled, “If I didn’t have five of your so-called Grade 1 concussions a game, that meant I was inactive. You guys are a joke.” And he stormed out of the meeting.
Plummer said he felt reassured by “being lied to by the NFL.” He worked for years as a radio analyst for the 49ers, but when he started doing work for the Pac-12 Network, he struggled with memory.
“I couldn’t think fast,” he said.
Plummer also suffered from depression, especially after the suicide of his good friend and former teammate Junior Seau. Plummer went to get a diagnosis from a forensic neurologist because he wanted to know his medical status before any settlement in the class action suit between the NFL and thousands of former players and relatives of deceased players was finalized. A resolution in that case is expected later this year.
Borland’s unexpected retirement prompted an outpouring of response on social media. Many, including notable former players, praised Borland for putting his health first. Some football fans attacked Borland for being “soft.”
Radio analyst angry
The 49ers radio analyst Tim Ryan told KNBR that he was angry about Borland’s decision because he liked watching him play. He also differentiated between recent player departures by saying “Patrick Willis retired, Chris Borland quit.” In the world of sports, there are few condemnations harsher than saying a player quit.
Borland’s decision may look different 30 years from now. More and more players will weigh health risks against potential riches and fame — especially in a league that doesn’t have guaranteed contracts and has woefully inadequate post-career health care.
Though the popularity of the NFL is at a record high, studies show the number of kids playing youth football is on the decline. And it’s not just mothers who fear having their children play football.
“It’s become a conversation with fathers now, who have to acknowledge the dangers of football,” Plummer said.
That has to be a major concern for the NFL. So is the fact that so many of its fans think Chris Borland is doing the right thing.
MENLO PARK, Calif., March 5, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, announced today that Atlanta-based Shepherd Center, one of the nation's top rehabilitation hospitals for spinal cord injury and brain injury, has commenced enrollment for the Phase 1/2a clinical trial of AST-OPC1 (oligodendrocyte progenitor cells) in newly injured patients with sensory and motor complete cervical spinal cord injury (SCI).
The Phase 1/2a trial follows the successful completion of the Phase 1 trial of AST-OPC1, which met its primary endpoints of safety and feasibility when administered to five patients with neurologically complete, thoracic SCI. Shepherd Center was a site in the Phase 1 study and enrolled two of the five subjects in that study. Asterias intends to initiate enrollment for the Phase 1/2a trial at up to seven additional sites in the coming months.
Richard G. Fessler, MD, PhD, professor of neurological surgery at Rush University Medical Center and principal investigator for the Phase 1 clinical trial, said, "There are currently no FDA-approved therapeutics or devices for the more than 12,000 individuals who sustain an SCI each year in the United States alone, or for the approximately 1.3 million Americans who are estimated to be living with an SCI. If AST-OPC1 could deliver even modest improvements in motor or sensory function, it would result in significant improvements in quality of life."
The Phase 1/2a clinical trial is designed to assess safety and activity of escalating doses of AST-OPC1 for complete cervical SCI, the first targeted indication for AST-OPC1. The trial will be an open-label, single-arm study testing three escalating doses of AST-OPC1 in patients with sub-acute, C-5 to C-7, neurologically complete cervical SCI. These individuals have essentially lost all sensation and movement below their injury site with severe paralysis of the upper and lower limbs. AST-OPC1 will be administered 14 to 30 days post-injury. Patients will be followed by neurological exams and imaging methods to assess the safety and activity of the product.
The Phase 1/2a clinical trial is designed to assess safety and activity of escalating doses of